| 1 |
Longstreth GF, Thompson WG, Chey WD, Houghton LA, Mearin F, Spiller RC. Functional bowel disorders. Gastroenterology 2006;130:1480-1491.
DOI
|
| 2 |
Chey WD, Kurlander J, Eswaran S. Irritable bowel syndrome: a clinical review. JAMA 2015;313:949-958.
DOI
|
| 3 |
Rodriguez-Fandino O, Hernandez-Ruiz J, Schmulson M. From cytokines to toll-like receptors and beyond - current knowledge and future research needs in irritable bowel syndrome. J Neurogastroenterol Motil 2010;16:363-373.
DOI
|
| 4 |
Ohman L, Isaksson S, Lindmark AC, et al. T-cell activation in patients with irritable bowel syndrome. Am J Gastroenterol 2009;104:1205-1212.
DOI
|
| 5 |
Cremon C, Gargano L, Morselli-Labate AM, et al. Mucosal immune activation in irritable bowel syndrome: gender dependence and association with digestive symptoms. Am J Gastroenterol 2009;104:392-400.
DOI
|
| 6 |
Barbara G, De Giorgio R, Stanghellini V, Cremon C, Corinaldesi R. A role for inflammation in irritable bowel syndrome? Gut 2002;51(suppl 1):i41-i44.
DOI
|
| 7 |
Kassinen A, Krogius-Kurikka L, Makivuokko H, et al. The fecal microbiota of irritable bowel syndrome patients differs significantly from that of healthy subjects. Gastroenterology 2007;133:24-33.
DOI
|
| 8 |
Camilleri M, Gorman H. Intestinal permeability and irritable bowel syndrome. Neurogastroenterol Motil 2007;19:545-552.
DOI
|
| 9 |
Medzhitov R. Toll-like receptors and innate immunity. Nat Rev Immunol 2001;1:135-145.
DOI
|
| 10 |
Shukla R, Ghosahl U, Ranjan P, Ghoshal UC. Expression of toll-like receptors, pro-, and anti-inflammatory cytokines in relation to gut microbiota in irritable bowel syndrome: the evidence for its micro-organic basis. J Neurogastroenterol Motil 2018;24:628-642.
DOI
|
webmaster
